Estimation of serum and tissue level of interleukin-15 (IL-15) and IL-15 receptor alpha (IL-15Rα) in mycosis fungoides before and after phototherapy: An interventional cohort study.
IL-15
IL-15Rα
mycosis fungoides
phototherapy
Journal
Photodermatology, photoimmunology & photomedicine
ISSN: 1600-0781
Titre abrégé: Photodermatol Photoimmunol Photomed
Pays: England
ID NLM: 9013641
Informations de publication
Date de publication:
29 Dec 2023
29 Dec 2023
Historique:
revised:
25
10
2023
received:
02
06
2023
accepted:
28
11
2023
medline:
2
1
2024
pubmed:
2
1
2024
entrez:
29
12
2023
Statut:
aheadofprint
Résumé
Mycosis fungoides (MF) is a chronic, highly recurrent cutaneous T-cell lymphoma, whose pathogenesis has not yet been fully elucidated. Interleukin-15 was previously highlighted as a viability factor for cutaneous T-cell lymphoma with previous studies shedding light on its role in pathogenesis of MF and its plausibility as a potential therapeutic target. This study was conducted to evaluate serum and tissue expression of IL-15 and IL-15Rα in early cases of MF (IA, IB, IIA) at baseline and following phototherapy. Fourteen early MF cases were recruited. Samples were withdrawn prior to starting phototherapy treatment and following near complete clearance of the biopsied lesion or after a maximum of 36 sessions of phototherapy. Samples were assessed for change in expression of IL-15 and IL-15 Rα levels following treatment, whose levels were compared to healthy controls. Serum and tissue levels of IL-15 and IL-15Rα in early MF cases were significantly higher at baseline than their levels following phototherapy treatment and higher than healthy controls. However, they dropped significantly following treatment with no statistical difference between treated cases and controls, apart from serum IL-15Rα that remained significantly elevated than controls. Interleukin-15 and its receptor alpha appear to contribute to the pathogenesis of MF, being significantly elevated than healthy controls, which were normalized following phototherapy treatment, apart from serum IL-15Rα, which remained elevated. Controlling IL-15/IL-15Rα expression is a newly proposed mechanism of action of phototherapy in MF.
Sections du résumé
BACKGROUND
BACKGROUND
Mycosis fungoides (MF) is a chronic, highly recurrent cutaneous T-cell lymphoma, whose pathogenesis has not yet been fully elucidated. Interleukin-15 was previously highlighted as a viability factor for cutaneous T-cell lymphoma with previous studies shedding light on its role in pathogenesis of MF and its plausibility as a potential therapeutic target.
OBJECTIVE
OBJECTIVE
This study was conducted to evaluate serum and tissue expression of IL-15 and IL-15Rα in early cases of MF (IA, IB, IIA) at baseline and following phototherapy.
MATERIALS AND METHODS
METHODS
Fourteen early MF cases were recruited. Samples were withdrawn prior to starting phototherapy treatment and following near complete clearance of the biopsied lesion or after a maximum of 36 sessions of phototherapy. Samples were assessed for change in expression of IL-15 and IL-15 Rα levels following treatment, whose levels were compared to healthy controls.
RESULTS
RESULTS
Serum and tissue levels of IL-15 and IL-15Rα in early MF cases were significantly higher at baseline than their levels following phototherapy treatment and higher than healthy controls. However, they dropped significantly following treatment with no statistical difference between treated cases and controls, apart from serum IL-15Rα that remained significantly elevated than controls.
CONCLUSION
CONCLUSIONS
Interleukin-15 and its receptor alpha appear to contribute to the pathogenesis of MF, being significantly elevated than healthy controls, which were normalized following phototherapy treatment, apart from serum IL-15Rα, which remained elevated. Controlling IL-15/IL-15Rα expression is a newly proposed mechanism of action of phototherapy in MF.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Cerroni L. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):2-10. doi:10.12788/j.sder.2018.002
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70(2):205.e1-16; quiz 221-222. doi:10.1016/j.jaad.2013.07.04910
Ravat FE, Spittle MF, Russell-Jones R. Primary cutaneous T-cell lymphoma occurring after organ transplantation. J Am Acad Dermatol. 2006;54(4):668-675. doi:10.1016/j.jaad.2005.10.015
Rosen ST, Radvany R, Roenigk H, Terasaki PI, Bunn PA. Human leukocyte antigens in cutaneous T cell lymphoma. J Am Acad Dermatol. 1985;12(3):531-534. doi:10.1016/s0190-9622(85)70075-8
Olsen EA. Evaluation, diagnosis, and staging of cutaneous lymphoma. Dermatol Clin. 2015;33(4):643-654. doi:10.1016/j.det.2015.06.001
Pileri A, Guglielmo A, Grandi V, et al. The microenvironment's role in mycosis fungoides and Sézary syndrome: from progression to therapeutic implications. Cell. 2021;10(10):2780. doi:10.3390/cells10102780
Rückert R, Asadullah K, Seifert M, et al. Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol Baltim Md 1950. 2000;165(4):2240-2250. doi:10.4049/jimmunol.165.4.2240
Allard-Chamard H, Mishra HK, Nandi M, et al. Interleukin-15 in autoimmunity. Cytokine. 2020;136:155258. doi:10.1016/j.cyto.2020.155258
Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043-1049. doi:10.1038/nm.3645
Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;38:621-648. doi:10.1146/annurev-immunol-100919-023531
Döbbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood. 1998;92(1):252-258.
Leroy S, Dubois S, Tenaud I, et al. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Br J Dermatol. 2001;144(5):1016-1023. doi:10.1046/j.1365-2133.2001.04192.x
Marzec M, Liu X, Kasprzycka M, et al. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood. 2008;111(4):2181-2189. doi:10.1182/blood-2007-06-095182
Mishra A, La Perle K, Kwiatkowski S, et al. Mechanism, consequences and therapeutic targeting of abnormal IL-15 signaling in cutaneous T-cell lymphoma. Cancer Discov. 2016;6(9):986-1005. doi:10.1158/2159-8290.CD-15-1297
Asadullah K, Haeussler-Quade A, Gellrich S, et al. IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Exp Dermatol. 2000;9(4):248-251. doi:10.1034/j.1600-0625.2000.009004248.x
Willerslev-Olsen A, Litvinov IV, Fredholm SM, et al. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF). Cell Cycle. 2014;13(8):1306-1312. doi:10.4161/cc.28256
Hair follicle-derived IL-7 and IL-15 mediate skin-resident memory T cell homeostasis and lymphoma - PubMed. https://pubmed.ncbi.nlm.nih.gov/26479922/. Accessed May 8, 2023.
Kasprzycka M, Zhang Q, Witkiewicz A, et al. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol Baltim Md 1950. 2008;181(4):2506-2512. doi:10.4049/jimmunol.181.4.2506
Guo Y, Luan L, Patil NK, Sherwood ER. Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent. Cytokine Growth Factor Rev. 2017;38:10-21. doi:10.1016/j.cytogfr.2017.08.002
Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2014;20(8):2044-2050. doi:10.1158/1078-0432.CCR-12-3603
Di Sabatino A, Calarota SA, Vidali F, Macdonald TT, Corazza GR. Role of IL-15 in immune-mediated and infectious diseases. Cytokine Growth Factor Rev. 2011;22(1):19-33. doi:10.1016/j.cytogfr.2010.09.003
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70(2):223.e1-17; quiz 240-242. doi:10.1016/j.jaad.2013.08.033
Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053-1063. doi:10.1016/j.jaad.2005.08.057
Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of cancer (EORTC). Blood. 2007;110(6):1713-1722. doi:10.1182/blood-2007-03-055749
El-Mofty MA, Mostafa WZ, Esmat SM, et al. Protocol of Kasr Al-Ainy's phototherapy unit − Cairo University for the management of photoresponsive skin diseases − part 1: general protocol. J Egypt Women's Dermatol Soc. 2022;19(3):145-151. doi:10.4103/jewd.jewd_58_21
Phyo ZH, Shanbhag S, Rozati S. Update on biology of cutaneous T-cell lymphoma. Front Oncol. 2020;10:765. doi:10.3389/fonc.2020.00765